This page shows the latest Joerg Moeller news and features for those working in and with pharma, biotech and healthcare.
Bayer is revamping its structure, combining all its R&D research units into one division that will be headed by Joerg Moeller, current head of development. ... Moeller, who has been head of Bayer’s pharma division since 2014, officially takes over the
However, the study provides important clinical data for this difficult-to-treat disease,” commented Bayer’s head of development Joerg Moeller.
Patients with ESUS currently have limited treatment options and the role of anticoagulants in this area remains uncertain,” said Joerg Moeller, Bayer's head of development.
Dr Joerg Moeller, member of the executive committee of Bayer AG’s pharmaceutical division and head of development, said the work would build on a phase II study of vilaprisan that
Dr Joerg Moeller, Bayer's head of development.
Effective treatment options are urgently needed for patients with liver cancer,” said Joerg Moeller, Bayer's pharma head, who noted that Stivarga could now sit alongside Nexavar as "the second proven
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....